SCHEMBL4362210

SCHEMBL4362210

Cc1ccccc1CN(Cc1ccccc1C)C(CO)Cc1cc(F)cc(F)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.36
CCR3 P51677 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HCRTR1 O43613 1/20 0.32
MAPT P10636 1/20 0.32
HSP90AA1 P07900 1/20 0.32
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
EGFR P00533 1/20 0.31
ERBB2 P04626 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31
KCNH2 Q12809 1/20 0.31
NR3C1 P04150 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362215 1.00 TAS2R14 (0.36) TAS2R14CCR3MEN1KMT2AALDH1A1
SCHEMBL8268882 0.81 KMT2A (0.42) TAS2R14MEN1KMT2ASLC6A2SLC6A4
SCHEMBL5063362 0.81 KMT2A (0.42) TAS2R14MEN1KMT2ASLC6A2SLC6A4
SCHEMBL3855298 0.77 MEN1 (0.34) TAS2R14CCR3MEN1KMT2AALDH1A1
SCHEMBL3855296 0.77 MEN1 (0.34) TAS2R14CCR3MEN1KMT2AALDH1A1
SCHEMBL4365860 0.73 KDM4E (0.37) ALDH1A1CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL11970442 0.71 SLC1A1 (0.48) TAS2R14MEN1KMT2A
SCHEMBL475654 0.71 SLC1A1 (0.48) TAS2R14MEN1KMT2A
SCHEMBL269405 0.67 ALDH1A1 (0.47) TAS2R14MEN1KMT2AALDH1A1
SCHEMBL269406 0.67 ALDH1A1 (0.47) TAS2R14MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP TAS2R14 4701/4885CCR3 4494/4885MEN1 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.